Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has paid clinical milestone payment to MorphoSys related to the filing of clinical trial application for a phase 1 trial of a HuCAL-derived antibody.
Subscribe to our email newsletter
With this milestone, Boehringer Ingelheim and MorphoSys have reached eighth clinical milestone during the year 2010.
MorphoSys’ clinical pipeline now comprises 10 partnered programs in Phase 1 and five in Phase 2 development as well as the company’s proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.
MorphoSys chief scientific officer Marlies Sproll said in 2010, they saw eight clinical milestones reached with five different partners which surpassed their original expectations for the year of up to six such events.